Effects of combined use of antiretroviral agents and atypical antipsychotics on lipid parameters

Krystal L. Edwards, Lisa M. Chastain, Lauren Snodgrass, Amy Martin, Anthony J. Busti

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Human immunodeficiency virus (HIV) and psychiatric disorders frequently occur together and may result in concurrent use of atypical antipsychotic (AAP) agents and highly active antiretroviral therapy (HAART). Both classes of agents have been shown to cause clinically important dyslipidemia and metabolic dysregulation in a population at high baseline cardiovascular risk. The combined effects of concurrent use of these drug classes on lipids and other metabolic indices remain undetermined. This retrospective cohort included HIV(+) or HIV(-) patients at the Dallas Veterans Affairs Medical Center who received either HAART or AAP agents. Subjects were separated into three groups: HAART+AAP, HAART alone, and a control group of HIV(-) patients taking AAP agents. The combined HAART and AAP use on lipid parameters was examined. Included patients received treatment for at least 12 weeks and had baseline and follow-up lipids within 1 year. A total of 107 male patients were analyzed with a mean age of 51 years. Mean time on HAART regimen was 49 months (HAART+AAP; n=27) and 24 months (HAART alone; n=40), and mean time on AAPs was 20 months (HAART+AAP) and 22 months (AAP alone; n=40). The addition of an AAP agent to medication regimens in HIV(+) patients, resulted in trends toward worsening TC, LDL, and non- HDL cholesterol levels, although not statistically significant. Ratios of TC/HDL were insignificant between groups following initiation of HAART alone, AAP alone, or in combination; however a greater TG/HDL ratio was noted in those receiving HAART+AAP relative to HAART or AAP alone.

Original languageEnglish (US)
Pages (from-to)34-39
Number of pages6
JournalJournal of Antivirals and Antiretrovirals
Volume3
Issue number3
DOIs
StatePublished - Sep 27 2011

Fingerprint

Anti-Retroviral Agents
Highly Active Antiretroviral Therapy
Antipsychotic Agents
Lipids
HIV
Veterans
Dyslipidemias
LDL Cholesterol
HDL Cholesterol
Psychiatry

Keywords

  • Antiretrovirals
  • Atypical antipsychotics
  • Lipids

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this

Effects of combined use of antiretroviral agents and atypical antipsychotics on lipid parameters. / Edwards, Krystal L.; Chastain, Lisa M.; Snodgrass, Lauren; Martin, Amy; Busti, Anthony J.

In: Journal of Antivirals and Antiretrovirals, Vol. 3, No. 3, 27.09.2011, p. 34-39.

Research output: Contribution to journalArticle

Edwards, Krystal L. ; Chastain, Lisa M. ; Snodgrass, Lauren ; Martin, Amy ; Busti, Anthony J. / Effects of combined use of antiretroviral agents and atypical antipsychotics on lipid parameters. In: Journal of Antivirals and Antiretrovirals. 2011 ; Vol. 3, No. 3. pp. 34-39.
@article{73401858212b4e2eb4dcf59b52b7b43c,
title = "Effects of combined use of antiretroviral agents and atypical antipsychotics on lipid parameters",
abstract = "Human immunodeficiency virus (HIV) and psychiatric disorders frequently occur together and may result in concurrent use of atypical antipsychotic (AAP) agents and highly active antiretroviral therapy (HAART). Both classes of agents have been shown to cause clinically important dyslipidemia and metabolic dysregulation in a population at high baseline cardiovascular risk. The combined effects of concurrent use of these drug classes on lipids and other metabolic indices remain undetermined. This retrospective cohort included HIV(+) or HIV(-) patients at the Dallas Veterans Affairs Medical Center who received either HAART or AAP agents. Subjects were separated into three groups: HAART+AAP, HAART alone, and a control group of HIV(-) patients taking AAP agents. The combined HAART and AAP use on lipid parameters was examined. Included patients received treatment for at least 12 weeks and had baseline and follow-up lipids within 1 year. A total of 107 male patients were analyzed with a mean age of 51 years. Mean time on HAART regimen was 49 months (HAART+AAP; n=27) and 24 months (HAART alone; n=40), and mean time on AAPs was 20 months (HAART+AAP) and 22 months (AAP alone; n=40). The addition of an AAP agent to medication regimens in HIV(+) patients, resulted in trends toward worsening TC, LDL, and non- HDL cholesterol levels, although not statistically significant. Ratios of TC/HDL were insignificant between groups following initiation of HAART alone, AAP alone, or in combination; however a greater TG/HDL ratio was noted in those receiving HAART+AAP relative to HAART or AAP alone.",
keywords = "Antiretrovirals, Atypical antipsychotics, Lipids",
author = "Edwards, {Krystal L.} and Chastain, {Lisa M.} and Lauren Snodgrass and Amy Martin and Busti, {Anthony J.}",
year = "2011",
month = "9",
day = "27",
doi = "10.4172/jaa.1000032",
language = "English (US)",
volume = "3",
pages = "34--39",
journal = "Journal of Antivirals and Antiretrovirals",
issn = "1948-5964",
publisher = "Omics Publishing Group",
number = "3",

}

TY - JOUR

T1 - Effects of combined use of antiretroviral agents and atypical antipsychotics on lipid parameters

AU - Edwards, Krystal L.

AU - Chastain, Lisa M.

AU - Snodgrass, Lauren

AU - Martin, Amy

AU - Busti, Anthony J.

PY - 2011/9/27

Y1 - 2011/9/27

N2 - Human immunodeficiency virus (HIV) and psychiatric disorders frequently occur together and may result in concurrent use of atypical antipsychotic (AAP) agents and highly active antiretroviral therapy (HAART). Both classes of agents have been shown to cause clinically important dyslipidemia and metabolic dysregulation in a population at high baseline cardiovascular risk. The combined effects of concurrent use of these drug classes on lipids and other metabolic indices remain undetermined. This retrospective cohort included HIV(+) or HIV(-) patients at the Dallas Veterans Affairs Medical Center who received either HAART or AAP agents. Subjects were separated into three groups: HAART+AAP, HAART alone, and a control group of HIV(-) patients taking AAP agents. The combined HAART and AAP use on lipid parameters was examined. Included patients received treatment for at least 12 weeks and had baseline and follow-up lipids within 1 year. A total of 107 male patients were analyzed with a mean age of 51 years. Mean time on HAART regimen was 49 months (HAART+AAP; n=27) and 24 months (HAART alone; n=40), and mean time on AAPs was 20 months (HAART+AAP) and 22 months (AAP alone; n=40). The addition of an AAP agent to medication regimens in HIV(+) patients, resulted in trends toward worsening TC, LDL, and non- HDL cholesterol levels, although not statistically significant. Ratios of TC/HDL were insignificant between groups following initiation of HAART alone, AAP alone, or in combination; however a greater TG/HDL ratio was noted in those receiving HAART+AAP relative to HAART or AAP alone.

AB - Human immunodeficiency virus (HIV) and psychiatric disorders frequently occur together and may result in concurrent use of atypical antipsychotic (AAP) agents and highly active antiretroviral therapy (HAART). Both classes of agents have been shown to cause clinically important dyslipidemia and metabolic dysregulation in a population at high baseline cardiovascular risk. The combined effects of concurrent use of these drug classes on lipids and other metabolic indices remain undetermined. This retrospective cohort included HIV(+) or HIV(-) patients at the Dallas Veterans Affairs Medical Center who received either HAART or AAP agents. Subjects were separated into three groups: HAART+AAP, HAART alone, and a control group of HIV(-) patients taking AAP agents. The combined HAART and AAP use on lipid parameters was examined. Included patients received treatment for at least 12 weeks and had baseline and follow-up lipids within 1 year. A total of 107 male patients were analyzed with a mean age of 51 years. Mean time on HAART regimen was 49 months (HAART+AAP; n=27) and 24 months (HAART alone; n=40), and mean time on AAPs was 20 months (HAART+AAP) and 22 months (AAP alone; n=40). The addition of an AAP agent to medication regimens in HIV(+) patients, resulted in trends toward worsening TC, LDL, and non- HDL cholesterol levels, although not statistically significant. Ratios of TC/HDL were insignificant between groups following initiation of HAART alone, AAP alone, or in combination; however a greater TG/HDL ratio was noted in those receiving HAART+AAP relative to HAART or AAP alone.

KW - Antiretrovirals

KW - Atypical antipsychotics

KW - Lipids

UR - http://www.scopus.com/inward/record.url?scp=80053066203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053066203&partnerID=8YFLogxK

U2 - 10.4172/jaa.1000032

DO - 10.4172/jaa.1000032

M3 - Article

AN - SCOPUS:80053066203

VL - 3

SP - 34

EP - 39

JO - Journal of Antivirals and Antiretrovirals

JF - Journal of Antivirals and Antiretrovirals

SN - 1948-5964

IS - 3

ER -